Ocular therapeutics company Novaliq said today that it inked a strategic licensing agreement with AFT Pharmaceuticals for the commercialization of its dry eye therapy, NovaTears, in Australia and New Zealand.
NovaTears is the Germany-based company’s 1st commercially available product indicated for the treatment of evaporative dry eye diseases.
Get the full story at our sister site, Drug Delivery Business News.
The post Novaliq, AFT Pharmaceuticals ink licensing deal for NovaTears dry eye therapy appeared first on MassDevice.